

Date: May 24, 2023

To,	To,
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza, C-1, Block G
Dalal Street,	Bandra Kurla Complex
Mumbai – 400 001	Bandra (E), Mumbai – 400 051
Scrip Code: 543434	Scrip Symbol: SUPRIYA

Dear Sir (s),

<u>Subject: Disclosure under regulation 30 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015</u>

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that we, Supriya Lifescience Limited have executed a long-term Supply and Sales Agreement (hereinafter "Agreement") on May 23, 2023, with a leading Company in Europe for the supply of Active Pharmaceutical Ingredient (API) for a period of 10 years. The business potential would be approximately 400 Mn INR per year at its peak. The peak volumes are expected to happen in FY 27.

Supriya Lifescience would be the exclusive supplier of this API.

We request you to kindly take the above information for your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973

Corporate office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507Fax: +91 22 26860011GSTIN: 27AALCS8686A1ZXCIN: L51900MH2008PLC180452E-mail: supriya@supriyalifescience.comWebsite: www.supriyalifescience.com